Bio-Rad Laboratories, Inc. Class B

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO.B and other ETFs, options, and stocks.

About BIO.B

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. 

CEO
Norman D. Schwartz
CEONorman D. Schwartz
Employees
7,450
Employees7,450
Headquarters
Hercules, California
HeadquartersHercules, California
Founded
1952
Founded1952
Employees
7,450
Employees7,450

BIO.B Key Statistics

Market cap
7.16B
Market cap7.16B
Price-Earnings ratio
49.00
Price-Earnings ratio49.00
Dividend yield
Dividend yield
Average volume
413.85
Average volume413.85
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$321.12
52 Week high$321.12
52 Week low
$244.54
52 Week low$244.54

Stock Snapshot

As of today, Bio-Rad Laboratories, Inc. Class B(BIO.B) shares are valued at $267.43. The company's market cap stands at 7.16B, with a P/E ratio of 49.00.

On 2026-05-26, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock opened at —, reached a high of —, and a low of —.

The Bio-Rad Laboratories, Inc. Class B(BIO.B)'s current trading volume is 0, compared to an average daily volume of 413.85.

During the past year, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock moved between $244.54 at its lowest and $321.12 at its peak.

During the past year, Bio-Rad Laboratories, Inc. Class B(BIO.B) stock moved between $244.54 at its lowest and $321.12 at its peak.

BIO.B News

Simply Wall St 20h
How Investors May Respond To Bio-Rad Laboratories Facing Elliott’s Activist Push Over Sartorius Stake

On May 18, 2026, Elliott Investment Management disclosed a significant stake in Bio-Rad Laboratories and began pressing the company to address what it describes...

How Investors May Respond To Bio-Rad Laboratories Facing Elliott’s Activist Push Over Sartorius Stake
TipRanks 2d
Bio-Rad price target raised to $310 from $290 at Wells Fargo

Wells Fargo raised the firm’s price target on Bio-Rad (BIO) to $310 from $290 and keeps an Equal Weight rating on the shares after meeting with management. The...

Simply Wall St 4d
Is It Time To Reassess Bio-Rad Laboratories After Its Recent 16% Weekly Surge?

If you are wondering whether Bio-Rad Laboratories at around US$287.74 is priced attractively or not, it helps to step back and look at what the recent share per...

Is It Time To Reassess Bio-Rad Laboratories After Its Recent 16% Weekly Surge?

Analyst ratings

50%

of 6 ratings
Buy
33.3%
Hold
50%
Sell
16.7%

More BIO.B News

Simply Wall St 6d
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus

Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (NYSE:BIO). The activist position signals potential pressure for changes in...

Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus

People also own

Based on the portfolios of people who own BIO.B. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.